Introduction
This document provides an overview of the YDB drug-coated balloon catheter, highlighting its unique features, specifications, and clinical trial results. It is intended for reference by medical professionals.

Specifications and Models
The YDB product features a finer crystalline structure for rapid drug absorption, utilizing a unique drug coating technology. It is suitable for treating primary coronary small vessel lesions with diameters ranging from ≥2.0 mm to ≤2.75 mm. Various models are available with different balloon diameters and lengths, each with specific nominal and burst pressures.

Drug Coating Technology
The YDB catheter employs crystalline paclitaxel, uniformly applied to the balloon surface, and is the only product using loversol as the drug carrier matrix. A special "fine-crystal-enhanced" spraying process ensures optimal drug absorption and prolonged efficacy.

Clinical Trial Results
A multicenter, randomized, controlled clinical trial involving 233 participants across 8 sites in China demonstrated the safety and efficacy of the YDB product. The primary endpoint was the target lesion diameter stenosis at 9 months post-procedure, showing non-inferiority to the control group. The incidence of adverse events was comparable to the control product, with no significant device-related adverse events.

Conclusion
The YDB drug-coated balloon catheter offers a safe and effective treatment for small vessel lesions, with enhanced drug absorption and sustained therapeutic effects. It is supported by robust clinical trial data.

Contact Information
Nanjing YDB Medical Technology Co., Ltd.
Address: Room 115 of 1F, 2F, 3F, 4F in building 10, No.129, Fengshan Road, Gaochun Economic Development Zone, Nanjing City, Jiangsu 211316, China
Phone: 025-56865078
Fax: 025-56865079
Website: www.ydbmed.com